Canaccord Genuity Maintains Buy on Biogen, Raises Price Target to $245

Canaccord Genuity analyst Sumant Kulkarni has maintained a 'Buy' rating on Biogen (NASDAQ: BIIB) and increased the price target from $230 to $245.